

# Gastric, Esophageal, and Gastroesophageal Junction Cancer (Adenocarcinoma) Pathways

Patient Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_

**Pathology:** \_\_\_\_\_

**Stage:** \_\_\_\_\_

**Line of Therapy:** \_\_ Neoadjuvant/Pre-Op \_\_ Adjuvant/Post-Op  
\_\_ 1<sup>st</sup> Line \_\_ 2<sup>nd</sup> Line \_\_ 3<sup>rd</sup> Line \_\_ 3<sup>rd</sup> Line+

**ECOG Performance Status:** \_\_\_\_\_ **ICD-10 Code:** \_\_\_\_\_

Will the patient be undergoing surgery? \_\_ Yes \_\_ No

Will the patient be undergoing radiation therapy? \_\_ Yes \_\_ No

## Primary Therapy | Resectable and Unresectable Disease

- Cisplatin and fluorouracil (5FU)
- Fluorouracil (5FU) and cisplatin with concurrent radiation therapy (RT)
- FLOT:** Fluorouracil (5FU), leucovorin, oxaliplatin, and docetaxel (Taxotere)
- Paclitaxel and carboplatin with concurrent RT

## Post-Operative Treatment

- Fluorouracil (5FU) and leucovorin with concurrent RT

## Recurrent/Metastatic or Locally Advanced/Inoperable Disease | HER2 Negative | First Line of Therapy (1<sup>st</sup> Line)

- Cisplatin and fluorouracil (5FU)
- Fluorouracil (5FU) and irinotecan (Camptosar)
- FLO/FOLFOX:** fluorouracil (5FU), leucovorin, and oxaliplatin
- FLP:** fluorouracil (5FU), leucovorin, and cisplatin

## Recurrent/Metastatic or Locally Advanced/Inoperable Disease | HER2 Positive | First Line of Therapy (1<sup>st</sup> Line)

- Cisplatin, fluorouracil (5FU), and trastuzumab (Herceptin)

## Recurrent/Metastatic or Locally Advanced/Inoperable Disease | Second Line of Therapy (2<sup>nd</sup> Line)

- Irinotecan (Camptosar)
- Paclitaxel

**Note:** Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.